Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK.

New era in precision medicine for pancreatic cancer Shutterstock

Image courtesy of Shutterstock

The investment will support the PRECISION Panc project which aims to develop personalised treatments for pancreatic cancer patients, improving the options and outcomes for a disease where survival rates have remained stubbornly low.

The work is being jointly led by researchers from the Cancer Research UK/Medical Research Council Oxford Institute for Radiation Oncology, the University of Glasgow, the Cancer Research UK Beatson Institute, the Cancer Research UK Glasgow Clinical Trials Unit, the University of Manchester, the Cancer Research UK Manchester Institute, the Institute for Cancer Research, and the Cancer Research UK Cambridge Institute. The Oxford team will be investigating the potential role of radiotherapy in personalised therapy.

Read more